Cirtuvivint

• Description:

  Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1].

• Product Name Alternative:

  SM08502

• UNSPSC:

  12352005

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cirtuvivint.html

• Purity:

  98.28

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(C1=CC(N2CCN(CC2)C)=NC=C1)NC3=NC=C4C=CC(C5=CN(C)N=C5)=CC4=C3

• Molecular Formula:

  C24H25N7O

• Molecular Weight:

  427.50

• References & Citations:

  [1]Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [2143917-62-6]